215 related articles for article (PubMed ID: 28883618)
1. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Jung DE; Park SB; Kim K; Kim C; Song SY
Sci Rep; 2017 Sep; 7(1):10921. PubMed ID: 28883618
[TBL] [Abstract][Full Text] [Related]
2. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Lee HS; Park SB; Kim SA; Kwon SK; Cha H; Lee DY; Ro S; Cho JM; Song SY
Sci Rep; 2017 Jan; 7():41615. PubMed ID: 28134290
[TBL] [Abstract][Full Text] [Related]
3. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
4. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.
Choi HS; Song JH; Kim IJ; Joo SY; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW; Bae EH
Sci Rep; 2018 Aug; 8(1):11546. PubMed ID: 30068917
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
Bae EH; Kim IJ; Song JH; Choi HS; Kim CS; Eom GH; Kim I; Cha H; Cho JM; Ma SK; Kim SW
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691015
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
8. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Iwahashi S; Ishibashi H; Utsunomiya T; Morine Y; Ochir TL; Hanaoka J; Mori H; Ikemoto T; Imura S; Shimada M
J Med Invest; 2011 Feb; 58(1-2):106-9. PubMed ID: 21372494
[TBL] [Abstract][Full Text] [Related]
9. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
[TBL] [Abstract][Full Text] [Related]
10. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
[TBL] [Abstract][Full Text] [Related]
11. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
Asgar MA; Senawong G; Sripa B; Senawong T
Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness.
Xie Y; Wang Y; Li J; Hang Y; Jaramillo L; Wehrkamp CJ; Phillippi MA; Mohr AM; Chen Y; Talmon GA; Mott JL; Oupický D
Theranostics; 2018; 8(16):4305-4320. PubMed ID: 30214622
[TBL] [Abstract][Full Text] [Related]
14. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
Wang C; Lv H; Yang W; Li T; Fang T; Lv G; Han Q; Dong L; Jiang T; Jiang B; Yang G; Wang H
Cancer Lett; 2017 Jul; 398():1-11. PubMed ID: 28385602
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
[TBL] [Abstract][Full Text] [Related]
16.
Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
[No Abstract] [Full Text] [Related]
17. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
Yoon GE; Jung JK; Lee YH; Jang BC; In Kim J
Naunyn Schmiedebergs Arch Pharmacol; 2020 Mar; 393(3):491-500. PubMed ID: 31655853
[TBL] [Abstract][Full Text] [Related]
18. The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
Wang Y; Zhang W; Chen L; Chen W; Xu S; Tang L; Yang Y; Li Q; Jiang Q; Miao L
Cell Oncol (Dordr); 2021 Aug; 44(4):907-916. PubMed ID: 34170484
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
20. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1.
Li Q; Xia X; Ji J; Ma J; Tao L; Mo L; Chen W
Oncotarget; 2017 May; 8(20):33621-33630. PubMed ID: 28422725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
